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SUMMARY
Lysophosphatidic acid (LPA) acts through high affinity G protein-coupled receptors to mediate a
plethora of physiological and pathological activities associated with tumorigenesis. LPA receptors
and autotaxin (ATX/LysoPLD), the primary enzyme producing LPA, are aberrantly expressed in
multiple cancer lineages. However, the role of ATX and LPA receptors in the initiation and
progression of breast cancer has not been evaluated. We demonstrate that expression of ATX or
each Edg-family LPA receptor in mammary epithelium of transgenic mice is sufficient to induce a
high frequency of late-onset, estrogen receptor (ER) positive, invasive and metastatic mammary
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cancer. Thus ATX and LPA receptors can contribute to the initiation and progression of breast
cancer.
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INTRODUCTION
Breast cancer remains the most frequent malignant tumor among North American women
(Jemal et al., 2007). Standard treatment modalities have improved the overall outlook and
quality of life. However, additional targeted therapeutics are needed due to the heterogeneity
of breast cancer and primary and acquired resistance to existing therapies. Transgenic mouse
models of human breast cancer have provided important information related to the initiation
and progression of breast cancer and emerged as powerful tools for preclinical research.
LPA is a bioactive phospholipid that acts as a growth factor by activating distinct high
affinity G protein-coupled receptors (GPCR) to elicit multiple cellular responses including
proliferation, survival, motility, invasion and production of growth factors and, in particular,
neovascularizing factors (Van Corven et al., 1989; Moolenaar et al., 2004). The endothelial
differentiation gene (Edg) GPCR subfamily (LPA1/Edg2, LPA2/Edg4 and LPA3/Edg7)
represents the most widely expressed and well-characterized LPA receptors. ATX, a
secreted enzyme, mediates the production of the majority of extracellular LPA by
hydrolyzing lysophosphatidylcholine, the most abundant lysophospholipid constituent in
circulation (Umezu-Goto et al., 2002). Indeed, mice with heterozygous loss of ATX have
approximately ½ the normal plasma levels of LPA (Van Meeteren et al., 2006). Although
ATX can produce sphingosine 1 phosphate in vitro, in vivo its activity appears to be
restricted to production of LPA (Van Meeteren et al., 2006; Pamulkar et al., 2009).
LPA was initially implicated in cancer pathophysiology by our demonstration that LPA is
present at elevated levels in ascites of ovarian cancer patients and activates ovarian and
breast cancer cells (Xu et al., 1995). Subsequent studies have implicated LPA and its
receptors in multiple functions in cancer cells including breast cancer lines (Sasagawa et al.,
1999; Fang et al., 2000; Shida et al., 2003; Umezu-Goto et al., 2004; Boucharaba et al.,
2004; Kitayama et al., 2004; Boucharaba et al., 2006; Chen et al., 2007; Horak et al., 2007).
LPA protects breast cancer cells from the effects of radiation and chemotherapy suggesting
that it could alter response to therapy in patients (Hu et al., 2005; Ishdorj et al., 2008). The
LPA1 receptor contributes to the metastasis of breast cancer xenografts to bone (Boucharaba
et al., 2004; Boucharaba et al., 2006). Further, LPA1 and the Nm23 metastases regulator are
inversely correlated in breast cancer tissues, implicating LPA1 in metastases (Horak et al.,
2007). LPA2 is markedly elevated in the majority of postmenopausal breast cancers
(Kitayama et al., 2004). Even though these studies suggest a potential contribution of LPA
and its receptors in breast tumorigenesis, the role of LPA receptors and/or ATX in initiation,
progression, metastases and outcome of breast cancer remains to be fully elucidated.
Furthermore, since LPA signals through GPCRs, which are targets of almost one half of all
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drugs (Schlyer et al., 2006), and since LPA receptor and ATX inhibitors are in preclinical
development (Baker et al., 2006; Murph et al., 2007; www.lpath.com), demonstration that
ATX or LPA receptors contribute to breast cancer initiation or progression would increase
the impetus for a concerted evaluation of LPA receptor and ATX antagonists as therapeutic
interventions. Evaluating the role of ATX and LPA receptors in breast cancer
pathophysiology as well as translating these concepts to effective patient therapy is
hindered, in part, by lack of suitable animal models.
In this study, we established transgenic mouse models expressing human ATX, the enzyme
producing LPA, and each of the three major LPA receptors (LPA1, LPA2 and LPA3) under
the MMTV-LTR promoter. Strikingly the expression of ATX or LPA1, LPA2 or LPA3 was
sufficient to result in a high frequency of late-onset mammary carcinomas with variable
incidence and metastatic rates.
RESULTS
ATX and LPA receptor levels in breast cancer correlate with clinical characteristics
As indicated by microarray analysis (Finak et al, 2008), ATX, LPA1, LPA2, and LPA3 are
expressed in both human breast epithelium and stroma (Figure S1A). Although LPA1 levels
appeared lower in human breast epithelium, there were no statistically significant
differences in levels in ATX, LPA1, LPA2, and LPA3 between stroma and epithelium. In
normal mammary glands of wild type FVB/N mice, LPA1, LPA3 and ATX were expressed
at significant levels (Figure S2). LPA2 was low to absent in the mammary gland. Based on
expression profiling of human breast cancers, ATX, LPA1, LPA2, and LPA3 are expressed
in most tumors with levels of LPA2 and LPA3 being increased in poorly differentiated
breast cancers (Sotiriou et al., 2006; Desmedt et al., 2007; Figure S1B; not presented). Thus
LPA receptor expression could contribute to patient outcomes.
Generation and characterization of MMTV–LPA and MMTV-ATX transgenic mice
To determine whether ATX or LPA edg-family LPA receptors could play a role in initiation
or progression during mammary tumorigenesis, we generated transgenic mice with wild
type, full length human ATX, or FLAG epitope tagged (due to the lack of useful isoform
specific antibodies) LPA1, LPA2 or LPA3 cDNA under the control of the MMTV-LTR
promoter (Figure 1A; Ngan et al., 2002). Integration of the construct into the genome of
FVB/N potential founders was screened by PCR and confirmed by Southern blotting of tail
DNA (Figure 1B). Three MMTV-LPA1 (#LPA1–2, #LPA1–7, #LPA1–27) and two MMTV-
LPA2 (#LPA2–3, #LPA2–6), MMTV-LPA3 (#LPA3–3, #LPA3–22) and MMTV-ATX
(#ATX 20, #ATX 21) founders passed the transgene through the germ line.
Transgenic mice were bred to activate the MMTV-LTR promoter, which contains
hormonally responsive elements activated by progestins and corticosteroids (Ma et al.,
1999). Real-time quantitative PCR analysis demonstrated expression of the ATX, LPA1,
LPA2 or LPA3 transgenes in mammary glands of multiparous female mice (day 18 of
second pregnancy, Figure 1C) with much higher levels than in virgin transgenic mice. Each
of the LPA receptors and ATX were expressed in transgenic mammary glands of
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multiparous mice based on western blotting (Figure 1D). A weak band was detected with the
ATX antibody in WT mice, likely representing endogenous ATX (Figure 1D, upper panel).
Transgene expression was also detectable in spleen, intestine, lung and uterus, albeit at
much lower levels than in mammary glands (Figure 1D), consistent with the reported
expression of the MMTV-LTR promoter (Sinn et al., 1987; Fromieu-Mourez et al., 2003).
To determine whether mammary epithelial-specific expression of LPA receptor or ATX
perturbed normal mammary gland development, we performed whole mount analyses on
mammary glands of 3 to 12-week-old virgin female transgenic mice. Transgenic mammary
glands showed a slight increase in side branching compared to WT females including
FVB/N and nontransgenic littermates (Figure 2). MMTV-LPA1, LPA2, LPA3 or MMTV-
ATX mice did not exhibit mammary gland abnormalities during gestation, were able to nurse
pups, and gave birth to multiple litters of expected size. Thus expression of LPA receptors or
ATX does not appear to significantly alter mammary gland development and function.
MMTV–LPAs or MMTV-ATX transgenic mice develop chronic mastitis, hyperplasia,
mammary intraepithelial neoplasia, invasive and metastatic tumors
Multiparous (3 times) and virgin female as well as male mice from at least two different
lines from the ATX, LPA1, LPA2 and LPA3 transgenic strains were monitored for tumor
development over 24 months, When the presence of a palpable mammary lesion was
detected or mice reached 24 months of age, mice were subjected to detailed
histopathological analysis by a veterinary pathologist (CS). No mammary cancers (including
mammary intraepithelial neoplasia, MIN) were observed in a cohort of 44 multiparous WT
mice including FVB/N and nontransgenic littermates, consistent with reported low
mammary tumor incidence (<1%) in FVB/N mice (Sinn et al., 1987; Fromieu-Mourez et al.,
2003). Furthermore, no mammary cancers were observed in virgin or male transgenic mice
(not presented).
Strikingly, the expression of ATX or LPA1, LPA2 or LPA3 receptors in the mammary gland
of at least two independent lines for each of the transgenes of multiparous mice was
sufficient to result in high frequency, albeit late-onset (ranging from 8 months to 24 months)
mammary carcinomas with variable incidence (Figure 3). There were varying frequencies of
abnormal proliferation (hyperplasia), non-invasive tumor formation (Mammary
intraepithelial neoplasia, MIN), invasive mammary carcinoma (IMC) and metastasis to other
organs (MMC) among the transgenic mice (Figure 4). There was a low incidence of mastitis
and mammary gland hyperplasia in non-transgenic mice at 22 months of age and over. In
contrast, mammary glands from MMTV-LPA receptor and MMTV-ATX mice demonstrated
a high frequency and early onset of chronic mastitis indicative of chronic inflammation prior
to development of tumors (Figure 4).
The incidence of mammary carcinoma was highest in LPA2 (52.8%) transgenic mice with
the earliest onset (average 16.5 months); in LPA1 transgenic mice, the incidence of
mammary carcinoma was the lowest (32.0%), with an average onset of 18.9 months; the
incidence in LPA3 transgenic mice was 42.3%, with the longest tumor-free period (average
19.5 months). 50% of ATX transgenic mice developed mammary carcinoma at an average
age of 20 months (Figure 3). The metastatic rate was highest in LPA3 (45.5%) transgenic
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mice with lower levels in other strains (Figure 4). Independent of strain, the sites of
metastasis were regional lymphoma nodes (70%) and lung (30%), while no metastatic bone
tumors were observed. The tumors encompassed adenocarcinomas (37.9%), adenosquamous
carcinomas (19.5%), or combined adenocarcinoma and adenosquamous carcinoma (13.8%)
with a major adenomatous component (total 71.2%), with MIN (14.9%), with other
histologies including carcinosarcoma and anaplastic carcinoma (13.9%) accounting for the
remainder (see Figure S3 for representative histology). All mammary carcinomas and
metastatic carcinomas assessed exhibited detectable levels of RNA (Figure S4A) and protein
(Figure S4B) for each of the transgenes, although at variable levels.
ER expression in mammary carcinomas
Most murine transgenic models are ER negative, limiting their applicability to the largest
class of human breast cancers, which are ER positive. We thus assessed the effect of LPA
receptors and ATX on ER expression in normal mammary glands and tumors. As indicated
in Figure 5A, in the wild type mammary gland, 10–15% of the epithelial cells are ER
positive compatible with previous studies (Figure 5A; Clarke et al., 1997; Zhang et al.,
2005). Strikingly, in the transgenic mice assessed, the fraction of ER, including nuclear ER,
positive cells was markedly enhanced in the mammary gland, especially in mammary ductal
hyperplasias, with 40–60% ER positive cells (Figure 5A). A subset of both primary and
metastatic tumors from transgenic mice had high ER levels, which was localized to the
nucleus (Figure 5B). As with tumor development and metastases, there was marked
variability in the fraction of tumors expressing ER (ATX: 62.5%; LPA1: 23.0%; LPA2:
21.8%; LPA3: 47.3%).
Expression of ATX and LPA receptors is associated with increased cytokine production
We have demonstrated that LPA is a potent inducer of IL-8 and vascular endothelial growth
factor (VEGF) (Hu et al., 2001; Fang et al., 2004; Yu et al., 2008). Serum levels of both
macrophage inflammatory protein 3 alpha (MIP-3α murine equivalent of IL-8) and VEGF
were significantly elevated in transgenic mice with mammary tumors (Figure 6).
Intriguingly, in transgenic mice prior to tumor development, there was a small but consistent
increase in MIP-3α and VEGF plasma levels suggesting that the increase in plasma MIP-3α
and VEGF precedes tumorigenesis (Figure 6). Whether the increase in MIP-3α and VEGF
represents a consequence of the inflammatory process associated with the chronic mastitis
present in the mice (Figure 4) or production of MIP-3α and VEGF by the increased number
of epithelial cells expressing ATX or LPA receptors will require further evaluation.
Effects of transgene expression on cellular signaling pathways
To elucidate effects of transgenic expression of ATX and LPA receptors on signaling
processes that could contribute to tumor initiation or progression, we used an emerging
technology, reverse phase protein arrays (RPPA). Wild type and transgenic mammary gland
and tumors from transgenic mice were assessed for presence or absence of tumor by
histology by a veterinary pathologist (CS). Based on unsupervised hierarchical clustering,
wild type mammary glands and a number of transgenic mammary glands form a cluster at
the bottom of the dendrogram (Figure 7A, samples list see Table S1). A middle cluster is
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composed primarily of transgenic mammary glands with a subset of transgenic mammary
tumors. The upper cluster is highly enriched for transgenic mammary cancers (Figure 7A).
Thus there appears to be a spectrum of proteomic changes from normal through transgenic
mammary gland to mammary cancer.
Normal mammary glands exhibited relatively high levels of ER, PR, GATA3, and BCL2
compatible with functional ER signaling. Relatively high levels of phosphorylation of the
EGFR, HER2, MKK3, MKK4, Stat1 and Stat6 are also present in normal epithelium.
Further both p53 and phospho-p53 are present at higher levels in normal tissues than in
tumor tissues. In contrast, mammary tumors demonstrated activation of the PI3K pathway as
indicated by phosphorylation of AKT, GSK3, mTOR, S6, and NF-κB with marked
activation in a subset of tumors. Intriguingly, PTEN levels were increased in the transgenic
tumors despite increases in signaling through the PI3K pathway (Figure 7A, S5). The
coordinate increase in AKT levels in the transgenic tumors as well as LPA receptor
activation could bypass the effects of elevated PTEN. Alternatively, the increase in PTEN
levels could be part of a feedback loop generated by activation of the PI3K pathway.
Increased phosphorylation was also observed in components of the MAPK pathways
(MAPK, p38, ATF-2) as well as other targets including Stat3 and PKCα. A number of
components of the Wnt pathway implicated in cell invasion and metastases including β-
catenin, cyclin D1 and c-Jun were elevated in of the mammary tumors, as well as E-
cadherin, an important contributor to inflammatory breast cancer (Kleer et al, 2001) (Figure
7A, S5).
Two of the transgenic tumors clustered with normal mammary tissue (LPA2–3 MC16 and
LPA3–3 MC8). This could be due to limited amounts of tumor present due to stromal
contamination. However, phosphorylation of AKT, GSK3, MAPK, NF-κB, ATF-2 was
increased in LPA2–3 MC16, while phosphorylation of p38 and c-Jun was increased in
LPA3–3 MC8 suggesting that signaling pathways were perturbed in these tumors.
The RPPA data was utilized to direct a series of Western blotting and IHC studies. Increased
p38, MAPK, ATF-2, PKCα, AKT, GSK3 and S6 phosphorylation was readily observed by
Western blotting (Figure 7B) and β-catenin by IHC in the transgenic tumors (Figure 7C).
The majority of the tumors assessed by Western blotting are represented in the top cluster in
Figure 7A, likely due larger tumors being used to produce sufficient protein for Western
blotting. This likely contributes to the high levels of phosphorylation observed in Figure 7B.
We used the RPPA to compare the transgenic ATX and LPA receptor mammary cancers
with MMTV-ErbB2, MMTV-Wnt1, MMTV-CD8-IGFIR, MMTV-IRS-1, and MMTV-IRS-2
transgenic mammary cancers on the same genetic background (Figure S6). As compared to
the other transgenic tumors, the ATX and LPA receptor transgenic tumors demonstrated
fewer changes in the targets assessed. Intriguingly, PTEN levels were elevated across all of
the tumor lineages despite increased signaling through the PI3K pathway as indicated by
increased S6 phosphorylation (Figure S6). As compared to other transgenic lines, a subset of
the ATX, LPA1, LPA2 and LPA3 tumors demonstrated elevated levels of pER, ER, PR and
GATA3 (Figure S6) compatible with retention of ER function in a subset of transgenic
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tumors (Figure 5). In terms of validating the proteomics approach, both HER2 and pHER2
were markedly elevated in MMTV-ErbB2 transgenic mice.
ATX and LPA receptor transgenic mice do not form a distinct group on transcriptional
profiling
As compared to transcriptional profiles of 13 different murine transgenic mammary cancer
models (Herschkowitz et al., 2007), the ATX and LPA receptor mammary tumors failed to
form distinct clusters, but rather were scattered throughout the different mammary tumor
models (Figure S7). Further several of the ATX and LPA receptor transgenic tumors
clustered most closely (but distinct from) to normal mammary glands. Thus the proteomics
and transcriptional profiling data are consistent and compatible with a model wherein the
ATX and LPA receptor transgenes allow accumulation of secondary mutations leading to
late onset mammary cancers.
DISCUSSION
In this study, we demonstrate that expression of ATX and each of the Edg family of LPA
receptors sensitizes to initiation and progression of breast cancer. This combined with the
observations that LPA1 and LPA2 receptors are aberrantly expressed in breast cancers
(Kitayama et al., 2004; Horak et al., 2007) and LPA2 and LPA3 receptor levels correlate
with tumor grade (Figure S1B) provides evidence supporting the contention that aberrant
expression of LPA receptors or the enzyme producing LPA could contribute to the initiation
and progression of human breast cancer. Importantly, these transgenic models combined
with the observation that inhibition of ATX or LPA receptors decrease metastases in human
xenograft models (Boucharaba et al., 2006; Baker et al., 2006) as well as the development of
ATX and LPA receptor inhibitors (Murph et al., 2007) establish ATX and LPA receptors as
potential targets for therapy in human breast cancer and provide models to evaluate the
efficacy of therapeutic interventions.
A recent study indicates that LPA1, LPA2 and LPA4 but not LPA3 are sufficient to induce
transformation of MEF expressing myc and Tbx2 (Taghavi et al., 2008). The transformation
of the MEF is associated with prolonged activation of signaling induced by LPA1, LPA2
and LPA4 but not LPA3. In contrast, LPA3 is sufficient to sensitize mammary epithelium to
tumorigenesis and LPA3 induces similar effects on cell signaling in the mammary tumors to
LPA1 and LPA2. The differences in effects of LPA3 on tumorigenesis in the two models
could be due to differential sensitivity of mammary epithelium and MEF to transformation
or alternatively to an interaction between LPA3 and the microenvironment in the transgenic
mammary model that is not recapitulated in the MEF in vitro.
Expression of each of ATX, LPA1, LPA2 or LPA3 was sufficient to induce late onset
mammary cancers in at least two lines for each transgene. Indeed, all of the lines that passed
the MMTV driven transgenes through the germline developed mammary tumors. The
induction of tumors required activation of the MMTV promoter with multiple pregnancies.
Further tumors were not observed in male or virgin transgenic mice or non-transgenic
littermates. Thus it is highly unlikely that the mammary tumors occur due to integration of
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the transgenes into other loci but rather represents an effect of expression of ATX and LPA
receptors on the initiation or progression of mammary tumors.
We have demonstrated that the Edg family of LPA receptors is pleiomorphic in function (Yu
et al., 2008). Indeed, while each of the LPA receptors preferentially link to particular
pathways and functional outcomes, the receptors retain the capability of inducing similar
signaling events and functional outcomes (Yu et al., 2008). Alternatively, ATX and the LPA
receptors by increasing cell viability, one of the major activities of LPA, could increase the
likelihood that mutations acquired over prolonged latent period would lead to tumor
development. Indeed, the ATX and LPA receptor driven tumors (Figure S7 and data not
shown), do not form a distinct cluster on functional proteomics or transcriptional profiling
and indeed demonstrate fewer aberrations than most transgenic models clustering closest to,
but distinct, from normal mammary glands. This is compatible with LPA production and
function increasing the susceptibility of mammary epithelium to a spectrum of secondary
transforming events.
As the major effect of ATX in vivo appears to be production of LPA (Van Meeteren et al.,
2006, Pamuklar et al., 2009), the ability of ATX to increase tumorigenesis suggests that
mammary epithelial cells express functional LPA receptors and are able to respond to LPA.
Indeed both human mammary epithelial cells and normal murine mammary glands express
LPA1, LPA2 and LPA3, albeit with low levels of LPA2 in murine mammary glands (Figure
S1, S2). Intriguingly, increasing circulating LPA levels by two fold by driving ATX
expression by alpha-1-antitrypsin (liver specific expression) is not sufficient to induce
mammary tumorigenesis (Pamulkar et al., 2009, and not presented) and further circulating
LPA levels are not elevated in the MMTV-ATX transgenic mice (not presented).
Unfortunately, there are no feasible approaches to determine the concentration of ATX in
the interstitial fluid so we are unable to determine the level of LPA at the cell surface of the
mammary epithelial cells. However, the increased tumorigenesis in the ATX transgenic
mice suggests that local production of LPA due to increased ATX levels is sufficient to
sensitize mammary epithelium to transformation. Enforced expression of LPA receptors in
MEF (Taghavi et al., 2008) or human ovarian cancer cells (Yu et al., 2008) is not sufficient
to induce ligand-independent signaling, but rather renders the cells more sensitive to
extracellular LPA and, in particular, prolongs cellular signaling. Thus, the increased tumor
development in the LPA receptor strains suggests that either LPA is produced locally, or that
circulating LPA (nM) is sufficient to activate the transgenic LPA receptors.
Current biological, transcriptional profiling and clinical approaches have classified human
ductal carcinomas into 3 major subtypes: estrogen receptor positive (ER), HER2 amplified
and triple negative or “basal” tumors which lack ER, PR and HER2 expression
(Herschkowitz et al., 2007). The “triple negative” or basal tumors are well represented in
transgenic models and multiple transgenic and knock-in HER2 tumors models are available;
however, there are few ER positive transgenic mouse models, particularly models that are
invasive and metastatic, limiting therapeutic and functional characterization of this
important type of cancer. Aberrant expression of LPA receptors and ATX enhanced ER
expression in mammary glands and many of the resultant mammary cancers were ER
positive, including metastatic tumors. Further a fraction of the transgenic tumors
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demonstrated nuclear ER staining as well as elevated phospho-ER, PR, GATA3 and BCL2
compatible with functional ER signaling. Together the data suggests that these transgenic
mouse models have the potential to mimic human breast cancer.
Functional proteomic analysis of the transgenic tumors demonstrated that both p38-MAPK
and ERK/MAPK were activated in a subset of the transgenic mammary cancers and in
particular in larger tumors. LPA activates p38-MAPK, ERK/MAPK pathways inducing
cancer cell invasion in vitro (Estrella et al., 2007; Hao et al., 2007) compatible with the
metastatic capacity of the transgenic tumors. An activated MAPK pathway, particularly in
concert with PI3K pathway activation increases expression of ATF-2 and NF-κB, two
master inflammatory transcription factors (Bhat et al., 2002; Patel et al., 2007). Indeed both
phosphorylated ATF-2 and NF-κB were present in a subset of the mammary tumors (Figure
7A, B). Activation of ATF-2 and NF-κB can induce cytokine production (Panne et al., 2007;
Balkwill et al., 2005) compatible with the increases in MIP-3α and VEGF in the serum of
transgenic mice prior to the development of tumors and the marked increases after tumor
development (Figure 6). The increases in MIP-3α and VEGF is consistent with our
demonstration that over-expression of the Edg family of LPA receptors enhances LPA-
induced production of cytokines, while silencing expression of the LPA receptors decreases
cytokine production (Yu et al., 2008). These cytokines may subsequently activate signal
transducer and activator of transcription (Stat) family members contributing to inflammation
and tumor formation (Wegenka et al., 1994; Bromberg et al., 1999; Li et al., 2007). Indeed,
phosphorylation of both Stat3 and Stat5 were increased in a subset of the transgenic
mammary tumors (Figure 7, S5). The LPA receptor and ATX transgenic mice demonstrated
a high frequency of chronic inflammation as indicated by mastitis, prior to the development
of MIN or malignancies. Further, both the local and metastatic tumors were associated with
a significant degree of lymphocytic infiltration. Thus inflammation may contribute to the
development of mammary cancers in the transgenic mice.
In a significant proportion of the murine tumors, the PI3K/AKT (protein kinase B, PKB)
pathway, which is implicated in breast cancer through frequent mutational activation and
increases in phosphorylation of AKT in tumors, is upregulated. The PI3K/AKT pathway has
been implicated in the development of resistance to endocrine therapy in breast cancer cell
lines and in the response to herceptin (Hennessy et al., 2005; Berns et al., 2007) suggesting
that ATX and LPA receptors may contribute to therapy resistance as well as tumorigenesis,
invasion and metastases.
LPA decreases p53 levels through activation of the PI3K–AKT pathway (Murph et al.,
2007; Aylon et al., 2007). The decrease in expression and phosphorylation of p53 in the
transgenic tumors suggests that deficient p53 function could contribute to tumor
development or progression to metastases (Hollstein et al., 1991; Bosco et al., 2007).
LPA induces the accumulation of β-catenin and induces the proliferation of colon cancer–
derived cell lines through activation of LPA2 and LPA3 (Yang et al., 2005). Compatible
with this observation, β-catenin levels as well as potential downstream effectors of the Wnt
pathway including c-Jun and cyclin D1, were increased in a fraction of the transgenic
mammary carcinomas. The increases in c-Jun and cyclin D1 are likely not mediated solely
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through Wnt signaling as the PI3K and MAPK pathways (Dearth et al., 2006), which are
activated in the transgenic mammary tumors, contribute to regulation of c-Jun and cyclin
D1.
In summary, aberrant expression of each of the Edg family of LPA receptors or the LPA
producing enzyme, ATX, in mammary glands is sufficient to sensitize transgenic mice to the
initiation and progression of breast cancer. Strikingly, the resultant tumors showed a broad
range of histotypes with inflammation, metastatic properties and were positive or negative
for the estrogen receptor mimicking human breast cancer. These transgenic models should
provide powerful tools for the understanding of the pathophysiology of breast cancer as well
as for the development and implementation of effective breast cancer therapeutics.
EXPERIMENTAL PROCEDURES
Plasmid construction
To generate a mammary gland transgenic vector containing FLAG-tagged LPA receptors or
ATX, we used MMTV-KCR (BS) (S. Tsai, Baylor College of Medicine, Houston, TX).
FLAG-LPA1, 2, 3 were transferred from pcDNA3.0-FLAG-LPA1, 2, 3 plasmids, containing
the FLAG-tagged full-length human LPA1, 2, or 3 cDNA, into pCR® II vector with a TA
cloning kit (Invitrogen). After sequence verification, the pCR® II FLAG-LPA1, 2, 3 vectors
were digested with EcoRI (for FLAG-LPA1, with partial digestion) to generate FLAG-LPA1,
2, 3 fragments, which were cloned into the EcoRI site of MMTV-KCR (BS) to generate
MMTV-KCR-FLAG-LPA1, 2, 3. The direction of the inserts was confirmed by restriction
mapping and DNA sequencing. The MMTV-KCR-FLAG-LPA1, 2, 3 plasmids were excised
to generate MMTV-KCR-FLAG-LPA1 (3.83 kb), MMTV-KCR-FLAG-LPA2 or MMTV-
KCR-FLAG-LPA3 (3.79 kb) vector-free fragments, containing long terminal repeats
(MMTV-LTR), which directs expression to the mammary epithelium. FLAG-tagged LPA1,
2, or 3, the partial exon II, intron II, exon III and a endogenous polyadenylation signal
derived from the rabbit β-globin gene (Ma et al., 1999) were used to generate transgenic
mice. We used the same method to prepare MMTV-KCR-ATX (5.3 kb), which includes the
MMTV-LTR sequence, full-length human ATX cDNA, rabbit β-globin intron and poly (A)
signal sequence.
Generation of transgenic mice
The MMTV-KCR-FLAG-LPA1, 2 or 3 or MMTV-KCR-ATX fragments were gel purified and
microinjected into pronucleii of single-cell embryos isolated from FVB/N mice in the the
Genetically Engineered Mouse Facility CCSG core. Zygotes were implanted into
pseudopregnant foster mothers. Offspring were screened for presence of the transgene using
PCR to amplify the region spanning the FLAG-tagged LPA1, 2, 3 or human ATX transgene.
The sequence of forward primer for LPA1, LPA2 and LPA3 is located in FLAG-tag,
ATGGACTACAAGGACGACGATG. The sequences of reverse primers are LPA1-reverse,
CTAAACCACAGAGTGGTCATTG; LPA2-reverse, CTAAAGGGTGGAGTCCATCAG;
LPA3-reverse, GGAAGTGCTTTTATTGCAGAC. The ATX primers are ATX-forward,
CCCAGAAATCCTGACACTCA and ATX-reverse, CCCATATGTCCTTCCGAGTG.
Southern hybridization with 15 µg of tail DNA digested with BamHI/XhoI, and probed with
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full length LPA1, 2, 3 cDNA or the StuI/EcoRI fragment of ATX as probe was used to
confirm founders. Transgenic mice were bred (with nontransgenic littermates and FVB/N
wild-type mice) to establish 3 independent transgenic lines of MMTV-LPA1 and 2 lines of
MMTV-LPA2, MMTV-LPA3 and MMTV-ATX. MMTV-LPA1, 2, 3 were bred to be
homozygous. For as yet unknown reasons, we were unable to create homozygous MMTV-
ATX mice. Female transgenic mice were bred three times to induce transgene expression
though activation of the hormone-dependent MMTV-LTR promoter, wild type FVB/N mice
and nontransgenic littermates were bred using the same conditions. F4- and F5-generation
mice were used for analysis at the RNA and protein level. All animal studies were carried
out under IACUC approved protocols. Mice were monitored weekly for the appearance of
tumors. All mice, whether tumors were obvious or not, were submitted for detailed
pathological analysis. Transgenic mice indicated as tumor free, did not have detectable
tumor masses or tumors on histological analysis. MMTV-ErbB2, MMTV-CD8-IGF-IR,
MMTV-IRS1, MMTV-IRS2 and MMTV-Wnt1 were bred and genotyped as previously
reported (Dearth et al., 2006; Carboni et al., 2005).
Real-time quantitative PCR
Total RNA was isolated using RNeasy Protect Mini Kit (Qiagen) according to the
manufacturer’s protocol. Taqman probes and Taqman One-Step RT-PCR master reagent
were from Applied BioSystems. Human and mouse LPA1, 2, 3 and ATX mRNA levels were
determined by Taqman real-time RT-PCR using the ABI PRISM 7700 Sequence Detection
System (Liu S et al., 2008).
Whole mount, histology and immunohistochemistry
The left inguinal mammary gland was excised from 3 to 12-week-old virgin female
transgenic mice and spread on glass slides for overnight fixation. The next day the samples
were hydrated, stained overnight in Carmine, and then dehydrated, precleared in toluene,
and stored in methyl salicylate.
To prepare sections, specimens of mammary glands or tumors were fixed with 10% formalin
for 24 h, embedded in paraffin and then sectioned at 5 µm thickness, followed by H&E
staining. For immunohistochemistry, specimens were blocked and incubated with rabbit
anti-mouse polyclonal antibody to ERα (1:400, Santa Cruz Biotechnology; Santa Cruz, CA)
or rabbit polyclonal antibody to β-catenin (1:50, Biosource, CA) at 4°C overnight, followed
by incubation with Goat anti-rabbit horseradish peroxidase-conjugated antibodies (1:500,
Bio-Rad, Hercules, CA). Mayer’s hematoxylin (Sigma) was used as a counter stain.
Measurement of MIP-3α and VEGF production by ELISA
Serum MIP-3α and VEGF from wild type and transgenic mice (18–22 months old) with and
without mammary carcinoma (MC) were quantified by ELISA using MIP-3α and VEGF
ELISA kits (R&D Systems). Concentrations were calculated by comparing the sample
absorbance to standard curves.
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Protein extracts were prepared from frozen mammary tissues by homogenization in ice-cold
X-100 lysis buffer (Liu et al., 2004). To assess FLAG expression, 5 µg of protein was
separated by SDS PAGE and transferred to imobilon prior to blocking with 5% milk and
incubating membranes with anti-FLAG M2 monoclonal antibody (Sigma) (1:7500),
followed by Goat anti-mouse horseradish peroxidase-conjugated antibodies (1:10,000) (Bio-
Rad, Hercules, CA). α-Tubulin was purchased from Cell Signaling (Beverly, MA); other
antibodies are listed in Table S2.
Transcriptional profiling
RNA was isolated from MMTV-LPA1, MMTV-LPA2, MMTV-LPA3 and MMTV-ATX (5
of each strain) mammary tumors using Qiagen RNAeasy kit according to the manufacturer’s
protocol, and assessed using Agilent 4×44K murine arrays (Herschkowitz et al., 2007). The
data were uploaded into the UNC Microarray Database where lowess normalization was
performed. The data from the 20 new arrays were combined with 146 arrays from
Herschkowitz et al and DWD (Benito et al., 2004) was used to correct for microarray
platform biases, followed by hierarchical cluster analysis using the mouse intrinsic gene set
(Herschkowitz et al., 2007).
Reverse phase protein array (RPPA)
The tissue lysates used for Western blot were also used for RPPA. Samples were mixed with
buffer [35% glycerol, 8% SDS, 0.25 mol/L Tris.HCl, pH 6.8, plus 10% β-ME without
Bromophenol Blue] and boiled for 5 minutes. Serial dilutions of samples were prepared and
diluted lysates transferred to a 384-well-plate, for printing with an automated robotic
GeneTac arrayer (Genomic Solutions, Inc., Ann Arbor, MI) as previously described (Zhang
et al., 2007; Tibes et al., 2006). Slides were staining with an automated robot (BioGenex,
San Ramon, CA). The antibodies used for RPPA are listed in Table S1.
Statistical analyses
The RPPA scanned slide images were quantified by MicroVigene software (version 2.9.9.7,
VigeneTech Inc., Carlisle, MA). Spot signal intensities were processed by in-house software
SuperCurve (version 0.997) (Hu et al., 2007), currently available as version 1.01 at the
repository “http://bioinformatics.mdanderson.org/OOMPA”. Three replicate samples from
the same lysate were averaged. Two sets of slides were run and normalized data was
combined using z-scores on each slide.
Hierarchical clustering in the rows (samples) and the columns (antibodies) used the
Euclidean distance and complete agglomeration in the heatmaps. p-values were obtained
from a one-way ANOVA followed by Dunnett’s test for each antibody. The F-test p-values
from the ANOVA were adjusted by Benjamini-Hochberg method (Benjamini et al., 1995),
for false discovery rate (FDR) control. Dunnett’s test p-values were reported only when the
F-test was significant at FDR = 0.05.
Mammary tumor free survival analysis was performed using the Kaplan-Meier method.
Differences in survival were determined using log-rank test (Harrington et al., 1982). Tumor
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incidence was compared between the genotype groups using Fisher’s exact test (Fisher,
1935; Clarkson et al., 1993). The analyses were performed using R (version 2.6.2) (R
Development Core Team, 2008).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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We demonstrate that ATX and LPA receptors play a causal role in breast tumorigenesis
by generating transgenic MMTV-LTR driven wild type human LPA receptor or ATX
mice. Mammary cancers occur in the absence of other oncogenic stresses, in a mammary
cancer resistant strain, FVB/N, and are frequently estrogen receptor (ER) positive,
invasive and metastatic - characteristics of human breast cancers that are rarely
recapitulated in murine models. Thus ATX and LPA receptors can contribute to breast
cancer initiation and progression. Since ATX and LPA receptor inhibitors are in
preclinical development, our work highlights LPA receptors and ATX as potential
therapeutic targets that could improve the outcome for breast cancer patients.
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Figure 1. Generation and characterization of transgenic mice
(A) The MMTV-LPA1, 2, 3 (a) or MMTV-ATX (b) transgenic constructs contain the 1.54 kb
MMTV-LTR and the full-length cDNA of FLAG-tagged human LPA receptors or full-
length human ATX linked to the KCR fragment containing the exon II (E2), intron II (I2),
exon III (E3) and polyadenylation signal (rβGpA) derived from rabbit β-globin. (B)
Southern analysis of BamHI/XhoI digested genomic DNA (15 µg) from potential founder
mice hybridized with full-length human LPA1, 2, 3 cDNA probes or StuI/EcoRI fragment of
hATX, genomic DNA from wild type FVB/N (WT), or other strain of edg family as control
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(C1, LPA1; C2, LPA2) for MMTV-LPAs. (C). ATX or LPA receptor transgene RNA
expression in mammary glands of virgin (V) and multiparous mice (MP, at day 18 of the 2nd
pregnancy) from different lines (L) were analyzed by Real-time quantitative PCR. D. ATX
or LPA receptor protein in transgenic mice, mammary gland (Mam. Gl), Salivary gland (Sal.
Gl).
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Figure 2. Effect of transgene expression in virgin murine mammary glands
Whole mount analyses of the fourth inguinal mammary glands of 8-week-old virgin mice.
Results are representative images from 6 mice of each group. The right column is
magnification of the left column. LN indicates lymph node.
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Figure 3. Mammary cancer incidence in female MMTV-ATX, or MMTV-LPA1, 2, 3 transgenic
mice
Female transgenic mice were bred 3 times to induce the MMTV-LTR promoter and
monitored for tumor incidence over 24 months with WT females including FVB/N and
nontransgenic littermates as controls. (A) Mammary cancers, large (1.5 × 2.0 × 1.6 cm,
black arrowhead) and small (0.5 × 0.5 × 0.5 cm, red arrowhead), developed in MMTV-
LPA2. (B) Kaplan-Meyer analysis of mammary cancers. (C) Mammary cancer incidence in
each line.
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Figure 4. Spectrum of mammary gland lesions
(A) Histopathology of mammary gland lesions in MMTV-LPAs or MMTV-ATX transgenic
mice. (a) Chronic mastitis with white blood cell infiltration (black arrowhead) & squamous
metaplasia (yellow arrowhead) of hyperplastic ducts (red arrowhead). (b) Mammary
intraepithelial neoplasia (MIN) (black arrowhead) with hyperplastic ducts (yellow
arrowhead) and chronic mastitis. (c) Invasive mammary adenocarcinoma. (d) Lymph node
metastatic carcinoma (black arrowhead). (e) Lung metastatic carcinoma (black arrowhead)
with pneumonia (scale 50 µm). (B) Representative mammary gland lesion histopathology.
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NM, normal mammary gland; Mastitis, chronic mastitis with squamous metaplasia;
Hyperplasia, hyperplasia (with chronic mastitis); MIN, mammary intraepithelial neoplasia
(with chronic mastitis and hyperplasia); IMC, invasive mammary carcinoma (with mastitis,
hyperplasia or MIN); MMC, metastatic mammary carcinoma.
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Figure 5. ER expression in mammary glands and mammary carcinomas from MMTV–LPAs or
MMTV-ATX
Paraffin sections of mammary carcinomas or mammary glands from adult transgenic mice
(20–22 month-old multiparous) were assessed for ER by immunohistochemical staining,
with normal mammary glands from WT multiparous mice as control (including FVB/N and
nontransgenic littermates). (A) ER expression in mammary glands of wild type FVB (a),
transgenic mice (b), or mammary ductal hyperplasia (c–e), (scale 50 µm). (B) ER expression
in tumors. (a) Mammary adenocarcinoma from MMTV-ATX; (b) Mammary
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adenocarcinoma from MMTV-LPA1; (c) Mammary lymph node metastatic adenocarcinoma
from MMTV-ATX; (d) Lung metastatic adenocarcinoma from MMTV-LPA3 (scale 100 µm).
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Figure 6. MIP-3α and VEGF production in MMTV-ATX or MMTV-LPA1, 2, 3 mice
Serum MIP-3α and VEGF in transgenic mice with and without mammary carcinoma (MC)
were quantified using MIP-3α and VEGF ELISA Kit. MIP-3α and VEGF concentrations
were calculated by comparing the absorbance of samples to standard curves. (A) MIP-3α;
(B) VEGF.
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Figure 7. Effects of transgene expression on cellular signaling pathways
(A) Variation in expression or phosphorylation of 50 proteins in 152 experimental samples
from 145 mice. Data are presented in a matrix format: each row represents an experimental
sample, and each column an antibody target. In each sample, the ratio of the abundance of
the molecule to its median abundance across all tissue samples is represented by the color of
the corresponding cell in the matrix (see scale, for expression levels). Dendrogram on left
shows similarities in the expression patterns between experimental samples. (B)
Phosphorylation of p38-MAPK, ERK/MAPK, ATF-2, NF-κB, pPKCα, AKT, GSK3α/β and
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S6 in mammary carcinomas (MC) from MMTV-ATX and MMTV-LPA1 2, 3 mice was
analyzed by Western blot. (C) Immunohistochemistry was performed on paraffin-embedded
mammary carcinoma sections. Specimens were blocked and incubated with rabbit
polyclonal antibody to β-catenin (detailed in Experimental procedures). β-catenin expression
in normal mammary gland of wild type female mice (a); mammary adenocarcinoma from
MMTV-LPA2 (b); mammary lymph node metastatic adenocarcinoma from MMTV-LPA2
and MMTV-ATX (c & d) (scale 50 µm).
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